Get the Stockscreener App
16.42
0.61%
0.10
After Hours:
16.60
0.18
+1.10%
Schrodinger Inc stock is traded at $16.42, with a volume of 1.12M.
It is up +0.61% in the last 24 hours and down -7.02% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$16.32
Open:
$16.35
24h Volume:
1.12M
Relative Volume:
1.14
Market Cap:
$1.21B
Revenue:
$193.35M
Net Income/Loss:
$-177.58M
P/E Ratio:
-6.702
EPS:
-2.45
Net Cash Flow:
$-172.43M
1W Performance:
-10.42%
1M Performance:
-7.02%
6M Performance:
-28.05%
1Y Performance:
-23.02%
1-Day Range:
$16.07
$16.75
1-Week Range:
$16.07
$18.34
52-Week Range:
$15.99
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
16.42 | 1.20B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
219.73 | 35.55B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
65.32 | 11.88B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
39.85 | 7.74B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
84.59 | 7.18B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
39.23 | 6.99B | 11.99B | 24.18M | 234.31M | 0.2956 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Neutral |
| Aug-15-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-14-25 | Initiated | Barclays | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
86,319 Shares in Schrodinger, Inc. $SDGR Acquired by Campbell & CO Investment Adviser LLC - MarketBeat
Stephens Investment Management Group LLC Trims Stock Holdings in Schrodinger, Inc. $SDGR - MarketBeat
Schrodinger (NASDAQ:SDGR) Shares Down 5.2%Time to Sell? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $91.37 Million Stock Holdings in Schrodinger, Inc. $SDGR - MarketBeat
(SDGR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Schrödinger Inc. stock could be next big winnerMarket Performance Report & Low Risk Entry Point Guides - Bộ Nội Vụ
Schrodinger stock rating reiterated at Buy by TD Cowen on strategic priorities By Investing.com - Investing.com South Africa
Assessing Schrödinger (SDGR) Valuation After Recent Uneven Share Price Momentum - Yahoo Finance
Schrödinger partners with Lilly TuneLab on AI drug discovery - Drug Target Review
Schrodinger stock rating reiterated at Buy by TD Cowen on strategic priorities - Investing.com Nigeria
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities - BioSpace
Schrödinger outlines 2026 priorities after strong 2025 By Investing.com - Investing.com Nigeria
Schrödinger outlines 2026 priorities after strong 2025 - Investing.com
Manas AI Secures Strategic Advantage through Unique Deep Integration with Schrödinger’s Physics + AI Discovery Platform - 01net
Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Chemoinformatics Market to Reach US$ 24.43 Billion by 2033 | CAGR - openPR.com
Schrodinger to offer Eli Lilly’s AI drug discovery platform on its software - WKZO
Will Schrödinger Inc. stock benefit from automation2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда
Schrodinger (NASDAQ:SDGR) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Schrödinger partners with Lilly TuneLab to enhance drug discovery By Investing.com - Investing.com Nigeria
Schrödinger, Inc.'s (NASDAQ:SDGR) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR? - simplywall.st
Schrödinger (SDGR) Partners with Eli Lilly for AI-Driven Drug Di - GuruFocus
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign - 01net
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software - Reuters
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery - MSN
Schrödinger (SDGR) Partners with Eli Lilly for AI Drug Discovery - GuruFocus
Eli Lilly in pact with Schrödinger in AI-related drug discovery - Seeking Alpha
Schrödinger partners with Lilly TuneLab to enhance drug discovery - Investing.com
Schrodinger (NASDAQ:SDGR) Upgraded to "Hold" at UBS Group - MarketBeat
Will Schrödinger Inc. stock recover faster than peersWeekly Trend Recap & Risk Managed Investment Signals - Улправда
Will Schrödinger Inc. stock beat EPS estimatesWeekly Trading Summary & Real-Time Price Movement Reports - Улправда
Is Schrödinger Inc. stock gaining market shareEarnings Recap Report & Reliable Volume Spike Alerts - Улправда
Whale Trades: Will Schrödinger Inc. stock benefit from automationQuarterly Profit Report & Accurate Buy Signal Alerts - Улправда
Schrodinger (SDGR): TD Cowen Maintains Buy Rating, Lowers Price Target | SDGR Stock News - GuruFocus
Schrodinger (NASDAQ:SDGR) Price Target Lowered to $24.00 at TD Cowen - MarketBeat
Why Schrödinger Inc. stock is rated strong buyJuly 2025 Update & Free Real-Time Volume Trigger Notifications - ulpravda.ru
KeyBanc Maintains Overweight Rating for SDGR but Lowers Price Ta - GuruFocus
KeyCorp Issues Pessimistic Forecast for Schrodinger (NASDAQ:SDGR) Stock Price - MarketBeat
KeyBanc Maintains Schrodinger(SDGR.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛
UBS Initiates Coverage of Schrödinger (SDGR) with Neutral Recommendation - Nasdaq
SDGR: UBS Initiates Coverage with Neutral Rating | SDGR Stock Ne - GuruFocus
Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade - Eastern Progress
Schrodinger stock initiated with Neutral rating at UBS on growth concerns - Investing.com Australia
Schrodinger stock initiated with Neutral rating at UBS on growth concerns By Investing.com - Investing.com South Africa
Schrodinger, Inc. (SDGR) Stock Analysis: Unveiling a 47% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Materials Informatics Market Size to Hit USD 736.71 Million by 2035 - GlobeNewswire Inc.
Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now - MSN
Do Options Traders Know Something About Schrodinger Stock We Don't? - MSN
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform - The Globe and Mail
Schrödinger (SDGR) Valuation Check After Analyst Upgrades Back Its Software-Focused Strategic Pivot - Yahoo Finance
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
2.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):